Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein levels.105”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
The cited source says what the claim attributes to it.
In the citing paper
“IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 11×
“Transfection of the indicated plasmids into NIH3T3 cells was performed using CaP04, as described previously (28). pM-v-src and pSG5-STAT3β are plasmid vectors expressing v-src and a dominant negative mutant of STAT3, respectively.”
MethodInfluentialSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897 · cited 2×
“Therefore, we used a tyrphostin inhibitor (AG-490) selective for the JAKfamily tyrosine kinases to determine whether inhibition of the pathway upstream of STAT activation would affect apoptosis in LGL leukemia cells (32).”
MethodWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826 · cited 2×
“The degree of binding was determined by electrophoretic analysis on a 5% native polyacrylamide gel as described previously (19, 31).”
BackgroundMethod
Cited by
Items 201–300 of 643
Uncovering the pathogenesis of large granular lymphocytic leukemia—novel STAT3 and STAT5b mutations
Rajala, H. L. M., Porkka, K., Maciejewski, J. P., Loughran, T. P., & Mustjoki, S. M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.882105 · Cited by 78
Self-citationOxysterol and Diabetes Activate STAT3 and Control Endothelial Expression of Profilin-1 via OSBP1
Romeo, G. R., & Kazlauskas, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710092200 · Cited by 79
Chen, W., Liu, L., Luo, Y., Odaka, Y., Awate, S., Zhou, H., Shen, T., Zheng, S., Lu, Y., & Huang, S. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0551 · Cited by 76
“Mcl-1 and survivin are positively regulated by Stat3 (45, 46).”
BackgroundGenomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia
Cheon, H., Xing, J. C., Moosic, K. B., Ung, J., Chan, V., Chung, D., Toro, M. F., Elghawy, O., Wang, J. S., Hamele, C. E., et al. (2022) · Blood · doi:10.1182/blood.2021013164 · Cited by 77
Self-citationZhan, Z., Li, Q., Wu, P., Ye, Y., Tseng, H.-Y., Zhang, L., & Zhang, X. D. (2012) · Autophagy · doi:10.4161/auto.8.1.18319 · Cited by 69
Barton, B. E., Karras, J. G., Murphy, T. F., Barton, A., & Huang, H. F.-S. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.11.3.1 · Cited by 72
Self-citationYao, X., Zhu, F., Zhao, Z., Liu, C., Luo, L., & Yin, Z. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23198 · Cited by 76
“Rabbit polyclonal antibodies to STAT3 and mouse monoclonal antibodies against GAPDH, Bcl-2, cIAP2, cyclin D1, Mcl-1, C-myc were obtained from Santa Cruz Biotechnology.”
BackgroundInfluentialTofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia
Bilori, B., Thota, S., Clemente, M. J., Patel, B. J., Jerez, A., Afable, M. G., & Maciejewski, J. P. (2015) · Leukemia · doi:10.1038/leu.2015.280 · Cited by 71
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70
“The most important biologic sequelae of JAK2-STAT3 pathway in MM cells is to maintain survival by regulating expression of downstream anti-apoptotic Bcl2 family proteins, including Bcl-XL, Mcl-1 and survivin [67,68].”
BackgroundEffect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres
Mukthavaram, R., Ouyang, X., Saklecha, R., Jiang, P., Nomura, N., Pingle, S. C., Guo, F., Makale, M., & Kesari, S. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0627-5 · Cited by 70
“[31] reported that induction of apoptosis was independent of BclXL regulation in large granular lymphocyte (LGL) leukemia.”
BackgroundMoutabian, H., Majdaeen, M., Ghahramani‐Asl, R., Yadollahi, M., Gharepapagh, E., Ataei, G., Falahatpour, Z., Bagheri, H., & Farhood, B. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02561-7 · Cited by 71
Sakamoto, E., Hato, F., Kato, T., Sakamoto, C., Akahori, M., Hino, M., & Kitagawa, S. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1104690 · Cited by 70
“It has been reported that STAT3 activation could induce several antiapoptotic molecules such as Bcl-2, Bcl-XL, Mcl-1, survivin, and cIAP2 according to the cell types and the stimuli used [1, 33–37].”
BackgroundZou, J., Rollison, D. E. M., Boulware, D. C., Chen, D.-T., Sloand, E. M., Pfannes, L. V., Goronzy, J. J., Bai, F., Painter, J. S., Wei, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.14 · Cited by 71
Self-citationOvercoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Koirala, M., & DiPaola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081801 · Cited by 75
“Increased MCL1 transcription can result from DEK transcription factor amplification [41] or constitutive activation of STAT3 [42].”
BackgroundCloning and characterization of a functional promoter of the human SOCS-3 gene
He, B., You, L., Uematsu, K., Matsangou, M., Xu, Z., He, M., McCormick, F. P., & Jablons, D. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03071-1 · Cited by 74
STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Lavecchia, A., Giovanni, C. D., & Novellino, E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843218 · Cited by 73
“These molecular events are exemplified by the constitutive activation of STAT3 mediated by the persistent stimulation of the IL-6/gp130 and the JAK/STAT pathways in multiple myeloma (MM), large granular lymphocyte (LGL) leukemia, and prostate cancer [18-20], as well as by elevated EGFR-mediated signaling and the activ…”
BackgroundZheng, Q., Liu, Y., Liu, W., Ma, F., Zhou, Y., Chen, M., Chang, J., Wang, Y., Yang, G., & He, G. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2175 · Cited by 68
Andersson, E. I., Rajala, H. L. M., Eldfors, S., Ellonen, P., Olson, T. L., Jerez, A., Clemente, M. J., Kallioniemi, O., Porkka, K., Heckman, C. A., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.65 · Cited by 70
“21,22 We recently confirmed that also LGL leukemia patients without STAT3 mutations have activation of STAT3 responsive genes.”
Self-citationKataoka, K., Kim, D. J., Carbajal, S., Clifford, J. L., & DiGiovanni, J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn061 · Cited by 65
Hideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Mitsiades, C. S., Mitsiades, N., Gong, B., Bonham, L., de Vries, P. W., et al. (2003) · PubMed · Cited by 78
Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation
Wood, K. (2009) · Frontiers in Bioscience · doi:10.2741/3487 · Cited by 64
“The PI3K and STAT3 (Signal Transducers and Activators of Transcription) pathway have been found to be upregulated in CD8 cells and PBMC from patients with LGL and play a role in this Fas resistance (78, 79).”
BackgroundAdvances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia
Cheon, H., Dziewulska, K. H., Moosic, K. B., Olson, K. C., Gru, A. A., Feith, D. J., & Loughran, T. P. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00565-6 · Cited by 70
“[47] It is believed that STAT3 activating mutations modulate the transcription of survival components such as anti-apoptotic Mcl-1[45] and these genetic lesions fuel LGL expansions.”
InfluentialSelf-citationNon‐canonical Stat3 signaling in cancer
Srivastava, J., & DiGiovanni, J. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22438 · Cited by 65
Savola, P., Brück, O. E., Olson, T. L., Kelkka, T., Kauppi, M. J., Kovanen, P. E., Kytölä, S. I., Sokka‐Isler, T., Loughran, T. P., Leirisalo‐Repo, M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.175729 · Cited by 64
Self-citationFrequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias
Olson, T. L., Cheon, H., Xing, J. C., Olson, K. C., Paila, U., Hamele, C. E., Neelamraju, Y., Shemo, B. C., Schmachtenberg, M., Sundararaman, S. K., et al. (2021) · Blood · doi:10.1182/blood.2020005831 · Cited by 65
Self-citationWang, M., Meng, B., Liu, Y., Yu, J., Chen, Q., & Liu, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485907 · Cited by 63
Liu, D., Hu, G.-Y., Long, G., Qiu, H., Mei, Q., & Hu, G. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.18 · Cited by 65
Lee, Y. K., Isham, C. R., Kaufman, S. H., & Bible, K. C. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0235 · Cited by 60
“Constitutive activation of STAT3 signaling has been observed in several neoplasms, including acute leukemias (5), breast cancer (6), and squamous cell carcinoma of the head and neck (7), mycosis fungoides (8), and large granular lymphocytic leukemias (9).”
BackgroundWang, Y., Ning, H., Ren, F., Zhang, Y., Rong, Y., Wang, Y., Su, F., Cai, C., Jin, Z. H., Li, Z., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.01.020 · Cited by 61
“…to upregulate the expression of many progrowth genes, including Bcl-xL, Mcl-1, cyclin D1, and c-Myc, which are required for tumor cell proliferation and survival (Bowman et al., 2001; Bromberg et al., 1999; Catlett-Falcone et al., 1999; Epling-Burnette et al., 2001; Grandis et al., 2000).”
BackgroundYang, M., Lee, H., Chen, C., Shen, C., & Ma, H. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150611013 · Cited by 63
“Intriguingly, increasing evidence has shown that the inhibition of activated STAT3 may contribute to cancer cell death and tumor regression [12], and the inhibition of STAT3 could suppress the growth of cancer cells by decreasing cell proliferation and enhancing the apoptosis of cancer cells [41,45].”
BackgroundTseng, L., Huang, P., Chen, Y.-R., Chen, Y., Chou, Y.-C., Chen, Y., Chang, Y.-L., Hsu, H., Lan, Y., Chen, K.-H., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188730 · Cited by 62
“STAT3 was found to be constitutively activated in numerous cancer types (Bowman et al., 2000; Bromberg, 2001, 2002; Epling-Burnette et al., 2001), and it was also reported that STAT3 mutations induce cellular transformation and tumor formation in vivo and that activation of STAT3 signaling further inhibits p53 transcr…”
BackgroundAcute and chronic neutropenias. What is new?
Palmblad, J. E. W., Papadaki, H. Α., & Eliopoulos, G. D. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00915.x · Cited by 60
Bard, J. D., Gélébart, P., Anand, M., Zak, Z., Hegazy, S. A., Amin, H. M., & Lai, R. L. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080982 · Cited by 59
Arulanandam, R., Vultur, A., Cao, J., Carefoot, E., Elliott, B. E., Truesdell, P. F., Larue, L., Feracci, H., & Raptis, L. H. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0469 · Cited by 63
“Inhibition of E-cadherin Engagement at Confluence Promotes Apoptosis Previous results have shown that Stat3 signaling contributes to the induction of antiapoptotic genes such as bcl-xL and mcl-1 (32, 33) while it down-regulates the p53 promoter (34), thus protecting tumor cells from apoptosis.”
BackgroundYu, R., Yu, R., & Liu, Z. (2017) · Human Cell · doi:10.1007/s13577-017-0188-4 · Cited by 60
“11) is as abundant as β-carotene in nature [8].”
BackgroundLiu, Y., Wang, L., Wu, Y., Lv, C.-W., Li, X., Cao, X., Yang, M. H., Feng, D., & Luo, Z. (2013) · Toxicology · doi:10.1016/j.tox.2012.12.018 · Cited by 58
Kandala, P. K., & Srivastava, S. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-9 · Cited by 59
“Activation of STAT3 at Tyr-705 leads to formation of a homodimer that translocates to the nucleus, where it binds to the promoter regions of several genes that transactivate STAT3-responsive genes such as Mcl-1, survivin and cyclin D1 [8-10].”
BackgroundGuasch, G., Ollendorff, V., Borg, J., Birnbaum, D., & Pébusque, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.23.8129-8142.2001 · Cited by 62
“STAT3 activation plays an important role in preventing apoptosis (26, 31).”
BackgroundBuettner, R., Huang, M., Gritsko, T., Karras, J., Enkemann, S., Mesa, T., Nam, S., Yu, H., & Jove, R. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0352 · Cited by 60
“STAT3 activation has been shown to provide cancer cells with a growth and survival advantage (9-13).”
BackgroundSelf-citationThe Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance
Witalisz‐Siepracka, A., Klein, K., Moser, B., & Stoiber, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947568 · Cited by 62
Stat3 Is Required for Full Neoplastic Transformation by the Simian Virus 40 Large Tumor Antigen
Vultur, A., Arulanandam, R., Turkson, J., Niu, G., Jove, R., & Raptis, L. H. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-12-1104 · Cited by 59
“Stat3 Inhibition Induces Apoptosis of Confluent, TAg-transformed Cells Previous results have shown that Stat3 signaling induces the antiapoptotic bcl-xL and mcl-1 genes, thus protecting tumor cells from apoptosis (Catlett-Falcone et al., 1999; Grandis et al., 2000; Epling-Burnette et al., 2001).”
BackgroundSelf-citationRole of STAT3 in Transformation and Drug Resistance in CML
Nair, R. R., Tolentino, J. H., & Hazlehurst, L. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00030 · Cited by 56
“REVIEW ARTICLE published: 10 April 2012 doi: 10.3389/fonc.2012.00030 Role of STAT3 in transformation and drug resistance in CML”
BackgroundInfluentialShibata, R., Kai, H., Seki, Y., Kato, S., Wada, Y., Hanakawa, Y., Hashimoto, K., Yoshimura, A., & Imaizumi, T. (2003) · Human Gene Therapy · doi:10.1089/104303403321618128 · Cited by 59
Kalvakolanu, D. V. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.01.002 · Cited by 59
“[414] Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al.”
BackgroundYin, W., Cheepala, S., Roberts, J. N., Chan, K. S., DiGiovanni, J., & Clifford, J. L. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-15 · Cited by 58
“It has been reported that Stat3 can regulate transcription of several Bcl-2 family proteins, such as Bcl-2 and Bcl-xL [28-31], Bax [32], and Mcl-1 [ 33-35 ].”
BackgroundZhang, Z.-R., Gao, M., & Yang, K. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4547 · Cited by 56
“STAT3 also upregulates anti-apoptotic proteins as Mcl-1 and Bcl-xL (63,64).”
Ihara, S., Kida, H., Arase, H., Tripathi, L. P., Chen, Y.-A., Kimura, T., Yoshida, M., Kashiwa, Y., Hirata, H., Fukamizu, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4062 · Cited by 55
“With regard to the role of Stat3 in promoting or inhibiting cancer, Stat3 has been implicated in the survival and proliferation of various cancer cells by upregulating the expression of various genes, including Bcl-xL (10), Mcl-1 (11), cyclin D1 (12), and cMyc (13).”
BackgroundLiu, H., Yang, J., Yuan, Y., Xia, Z., Chen, M., Xie, L., Ma, X., Wang, J., Ouyang, S., Wu, Q., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-98 · Cited by 63
“Multiple intracellular signaling pathways and transcription factors have been confirmed to influence Mcl-1 expression, including PI3K/ Akt [10], Stat3 [11,12], CREB [10], Ets family members Elk-1 [13] and PU.1 [14].”
BackgroundSelf-citationHamasaki, M., Hideshima, T., Tassone, P., Neri, P., Ishitsuka, K., Yasui, H., Shiraishi, N., Raje, N., Kumar, S., Picker, D. H., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3794 · Cited by 56
Barton, B. E., Murphy, T. F., Shu, P., Huang, H. F. S., Meyenhofen, M., & Barton, A. B. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1183.3.10 · Cited by 63
Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia
Teramo, A., Barilà, G., Calabretto, G., Vicenzetto, C., Gasparini, V. R., Semenzato, G., & Zambello, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00152 · Cited by 57
“Among these, the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling is central to direct the cell toward survival, being STAT an inducer of the transcription of many pro-survival genes (10).”
BackgroundBarrera, M., Aguilera, S., Castro, I., Matus, S., Carvajal, P., Molina, C., González, S., Jara, D., Hermoso, M. A., & González, M. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa670 · Cited by 57
Lee, D.-H., Sung, K. S., Bartlett, D. L., Kwon, Y. T., & Lee, Y. J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.11.013 · Cited by 59
Jo, M. J., Jeong, S., Yun, H. K., Kim, D. Y., Kim, B. R., Kim, J. L., Na, Y. J., Park, S. H., Jeong, Y. A., Kim, B. G., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5957-x · Cited by 54
Chen, J., Lan, T., Zhang, W., Dong, L., Kang, N., Zhang, S., Fu, M., Liu, B., Liu, K., & Zhan, Q. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1062 · Cited by 52
Dumitriu, B., Ito, S., Feng, X., Stephens, N., Yünce, M., Kajigaya, S., Melenhorst, J. J., Rios, O. J., Scheinberg, P., Chinian, F., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00227-6 · Cited by 54
Huang, H. F. S., Murphy, T. F., Shu, P., Barton, A. B., & Barton, B. E. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-2 · Cited by 55
“However aberrant signaling by STAT3 has been noted in many types of malignancies, such as myeloma, head and neck cancer, breast cancer, and prostate cancer [6-9].”
BackgroundDas, J., Das, S., Paul, A., Samadder, A., Bhattacharyya, S. S., & Khuda‐Bukhsh, A. R. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.01.009 · Cited by 53
Mees, C. D., Nemunaitis, J. J., & Senzer, N. N. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.73 · Cited by 59
STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin?
Jr., R. H. B. (2009) · CRC Press eBooks · doi:10.1201/9781498713764-13 · Cited by 50
Nabhani, S., Schipp, C., Miskin, H., Levin, C., Postovsky, S., Dujovny, T., Koren, A., Harlev, D., Bis, A.-M., Auer, F., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.05.021 · Cited by 53
STAT3 Contributes to Radioresistance in Cancer
Wang, X., Zhang, X., Qiu, C., & Yang, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01120 · Cited by 49
“Conversely, inhibiting STAT3 increases apoptosis (22, 23).”
Lin, Y., Wu, M.-H., Wei, T.-T., Chung, S.-H., Chen, K., Cheng, A., & Chen, C. (2012) · Neoplasia · doi:10.1596/neo.12300 · Cited by 49
“In addition, Src inhibition in some HNSCC cells leads to activation of STAT3, which upregulates its downstream antiapoptotic Bcl-XL and Mcl-1 proteins [44–46].”
CHOI, J., Ahn, M., PARK, C., Han, H., Kwon, S.-J., LEE, Y., & Kim, I. S. (2006) · Apmis · doi:10.1111/j.1600-0463.2006.apm_401.x · Cited by 51
The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor
Ecker, A. (2009) · Frontiers in Bioscience · doi:10.2741/3425 · Cited by 48
“Since Stat3 was reported to suppress Fas expression and to regulate Fas/FasL induced apoptosis in malignant T cells (21), we also analysed Fas and FasL expression.”
BackgroundWANG, X., ZHANG, Y., ZHANG, X., TIAN, W., FENG, W., & CHEN, T. (2012) · International Journal of Oncology · doi:10.3892/ijo.2011.1298 · Cited by 48
“also represents a survival factor for human cancer cells (23,41).”
BackgroundWang, T. T., Yang, J., Zhang, Y., Zhang, M., Dubois, S. P., Conlon, K. C., Tagaya, Y., Hamele, C. E., Dighe, S. A., Olson, T. L., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0290-y · Cited by 49
“Increased γc receptor signaling results in increased activation of downstream targets including STAT1/3/5, ERK, and Akt, which are strongly implicated in the pathogenesis of T-LGLL [15, 16, 23].”
InfluentialSelf-citationLarge granular lymphocytic leukaemia pathogenesis and management
Dearden, C. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08494.x · Cited by 48
Estradiol and Estrogen Receptor Agonists Oppose Oncogenic Actions of Leptin in HepG2 Cells
Shen, M., & Shi, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151455 · Cited by 53
“SOCS3/STAT3, a common signaling pathway shared by many cytokines including leptin to promote cell growth and oncogenesis [45,46], was assessed.”
BackgroundT-cell and natural killer-cell large granular lymphocyte leukemia neoplasias
Watters, R. J., Liu, X., & Loughran, T. P. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.593276 · Cited by 48
Self-citationActivation of Stat3 in renal tumors.
Guo, C. C., Yang, G., Khun, K., Kong, X., Levy, D. E., Lee, P., & Melamed, J. (2009) · PubMed Central · Cited by 47
Faletti, L. E., Ehl, S. R., & Heeg, M. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.03.003 · Cited by 49
“Other authors reported that repression of STAT3 in LGL leukemic cells down-regulated the survival protein Mcl-1, resulting in an increased sensitivity to apoptosis [73].”
BackgroundT cell large granular lymphocyte leukemia and chronic NK lymphocytosis
Barilà, G., Calabretto, G., Teramo, A., Vicenzetto, C., Gasparini, V. R., Semenzato, G., & Zambello, R. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.06.006 · Cited by 47
Liu, F., Jia, L., Wang, P., Wang, H., Farren, T., & Agrawal, S. G. (2016) · Oncotarget · doi:10.18632/oncotarget.8672 · Cited by 46
“The anti-apoptotic proteins Mcl-1 and Bcl-xL are target genes for both STAT3 and NF-κB [30, 33, 44, 45].”
BackgroundZhao, Y., Ma, K., Yang, S., Zhang, X., Wang, F., Zhang, X., Liu, H., & Fan, Q. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4409 · Cited by 48
STAT3beta, a distinct isoform from STAT3
Zhang, H., Yang, P.-L., Li, E., & Xu, L. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.02.006 · Cited by 45
Choi, H. J., & Han, J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.03.015 · Cited by 49
Thomas, J., Haseman, J. K., Goodman, J. I., Ward, J. M., Loughran, T. P., & Spencer, P. J. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm098 · Cited by 44
Self-citationGürbüz, V., Konaç, E., Varol, N., Yılmaz, A., Gürocak, S., Menevşe, S., & Sözen, S. (2014) · Oncology Letters · doi:10.3892/ol.2014.1795 · Cited by 45
“However, Epling-Burnette et al (48) previously found that the Bcl-2 family protein, MCL‐1, was significantly reduced by AG490 treatment.”
Henslee, A. B., & Steele, T. A. (2018) · Biomarker Research · doi:10.1186/s40364-018-0140-0 · Cited by 44
Kim, D., Park, G., Huuhtanen, J., Ghimire, B. R., Rajala, H. L. M., Moriggl, R., Chan, W. C., Kankainen, M., Myllymäki, M., & Mustjoki, S. M. (2021) · Leukemia · doi:10.1038/s41375-021-01296-0 · Cited by 45
“STAT activation in LGLL pathogenesis even in patients without STAT3 mutations has been suggested [1, 6, 12, 13].”
Survival signals in leukemic large granular lymphocytes
Epling‐Burnette, P. K., & Loughran, T. P. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)00135-5 · Cited by 44
Self-citationTargeting apoptosis in cancer chemotherapy
Makin, G. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.1.73 · Cited by 50
“Activated STAT 3 also transcriptionally upregulates Mcl-1 and increases resistance to Fas-induced apoptosis in large granular cell leukaemia [28].”
BackgroundSTAT3 Dysregulation in Mature T and NK Cell Lymphomas
Seffens, A., Herrera, A., Tegla, C., Buus, T. B., Hymes, K. B., Ødum, N., Geskin, L. J., & Koralov, S. B. (2019) · Cancers · doi:10.3390/cancers11111711 · Cited by 42
“Treatment with an antisense oligo against STAT3 resulted in decreased STAT3 protein levels, decreased Mcl-1 protein levels, and increased sensitivity to Fas-mediated apoptosis in T-LGL cells [66].”
BackgroundDrug repurposing towards targeting cancer stem cells in pediatric brain tumors
Bahmad, H. F., Elajami, M. K., Zarif, T. E., Bou-Gharios, J., Abouantoun, T. J., & Abou-Kheir, W. G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09840-2 · Cited by 43
“STAT3 activation plays a crucial role in the progression of many tumors, including brain tumors, by enhancing cancer cell growth, invasion, and metastasis while hindering apoptosis [124, 125].”
BackgroundZhang, X., Zhang, J., Wei, H., & Tian, Z. (2007) · Oncology Reports · doi:10.3892/or.17.6.1377 · Cited by 41
Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma
Lai, R., Rassidakis, G. Z., LIN, Q., Atwell, C., Medeiros, L. J., & Amin, H. M. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.07.011 · Cited by 42
“Activated/phosphorylated Stats (pStats) dimerize and translocate to the nucleus, where they act as transcriptional factors modulating the expression of many important apoptosis- and cell cycle– regulatory proteins, such as c-Jun, c-Kit, c-Myc, Bcl-XL, Bax, Bcl-2, Mcl-1, survivin, cyclins, p21, and p27 [14-19].”
BackgroundTherapeutic efficacy of FTY720 in a rat model of NK-cell leukemia
Liao, A., Broeg, K., Fox, T. E., Tan, S., Watters, R. J., Shah, M. V., Zhang, L. Q., Li, Y., Ryland, L. K., Yang, J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-331447 · Cited by 43
Self-citationBlockade of Notch signaling promotes acetaminophen-induced liver injury
Jiang, L., Ke, M., Yue, S., Xiao, W., Yan, Y., Deng, X., Ying, Q., Li, J., & Ke, B. (2017) · Immunologic Research · doi:10.1007/s12026-017-8913-3 · Cited by 43
“Inhibition of Stat3 signaling resulted in increased cell apoptosis [50].”
BackgroundMicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers
Sajjadi-Dokht, M., Mohammad, T. A. M., Rahman, H. S., Maashi, M. S., Danshina, S. D., Shomali, N., Solali, S., Marofi, F., Zeinalzadeh, E., Akbari, M., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.10.009 · Cited by 43
c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells
Allen, J. C., Talab, F., Zuzel, M., Lin, K., & Slupsky, J. R. (2011) · Blood · doi:10.1182/blood-2010-08-301176 · Cited by 44
Mcl-1 correlates with reduced apoptosis in neutrophils from patients with sepsis
Härter, L., Mica, L., Stocker, R. A., Trentz, O., & Keel, M. J. B. (2003) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2003.07.008 · Cited by 48
Guo, J. Q., Roberts, L., Chen, Z., Merta, P. J., Glaser, K. B., & Shah, O. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0114363 · Cited by 42
“Mcl-1 is a STAT transcriptional target [29,30,31] and was of particular interest as it has been shown to confer resistance to apoptosis following inhibition of Bcl-xL and Bcl-2 [10,12,13].”
BackgroundPétrin, D., Turcotte, S., Gilbert, A.-K., Rola‐Pleszczynski, M., & Staňková, J. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.05.021 · Cited by 45
Kim, B. H., Yin, C., Guo, Q., Bach, E. A., Lee, H., Sandoval, C., Jayabose, S., Ulaczyk‐Lesanko, A., Hall, D. G., & Baeg, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0309 · Cited by 45
STAT3 signaling is induced by intercellular adhesion in squamous cell carcinoma cells
Onishi, A., Chen, Q., Humtsoe, J. O., & Kramer, R. H. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.09.018 · Cited by 42
“Constitutive activation of STAT3 has been demonstrated in several human cancers, including breast cancer [3], prostate cancer [4], leukemia [5], lung cancer [6], thyroid cancer [7], and HNSCC [8].”
BackgroundChang, C. J., Chiang, C.-H., Song, W.-S., Tsai, S. K., Woung, L., Chang, C. H., Jeng, S.-Y., Tsai, C. Y., Hsu, C. C., Lee, H. F., et al. (2012) · Child s Nervous System · doi:10.1007/s00381-011-1672-x · Cited by 39
Self-citationT cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia
Shah, A., Diehl, L. F., & Clair, E. W. S. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.03.515 · Cited by 39
Xu, Y., Tabe, Y., Jin, L., Watt, J. C., McQueen, T. J., Ohsaka, A., Andreeff, M., & Konopleva, M. Y. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07130.x · Cited by 42
“The percentage of specific apoptosis was calculated using the following formula: [(% annexin V positive in the assay well) ) (% annexin V positive in the control well) · 100] / [100 ) (% annexin V positive in the control well)] (Epling-Burnette et al, 2001).”
MethodClinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias
Oshimi, K. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.8881 · Cited by 39
“Leukemic LGLs were found to display high levels of activated signal transducer and activator of transcription 3 (STAT3), and the treatment of leukemic LGLs with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity (58).”
Background
Metadata
- Authors
- Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., & Loughran, T. P.
- Affiliations
- University of South Florida (US)
- National Taiwan University (TW)
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 351-362
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC199188
- OpenAlex
- W2041204531
- Cited by
- 633
- References
- 60
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 31 · 2019: 22 · 2018: 14 · 2017: 27 · 2016: 15 · 2015: 27 · 2014: 46 · 2013: 31 · 2012: 35
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Moffitt Cancer Center
- National Institutes of Health (5r21ca078724-02)
- National Cancer Institute (R01CA055652, CA-55652, CA78724)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- large granular lymphocyte leukemia, STAT3 signaling, apoptosis, Mcl-1, Fas resistance, AG490, antisense oligonucleotides, Bcl-2 family proteins, v-Src
- MeSH terms
- Cell Line, DNA-Binding Proteins, Enzyme Inhibitors, Gene Expression Regulation, Humans, Leukemia, Neoplasm Proteins, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Trans-Activators, Oncogene Protein pp60(v-src), Apoptosis, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-bcl-2, Dimerization, Tyrphostins, STAT3 Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.